SEPTInvestingStart Free

VRDN 8-K: Fda approval

Viridian Therapeutics

Filed with the SEC on · accession 0001193125-26-452665

VRDN filed a 8-K (current report) with the SEC on Nov 9, 2026. Viridian Therapeutics announced positive Phase 1 clinical trial results for VRDN-008, a half-life extended bispecific FcRn inhibitor, demonstrating deep and sustained IgG reduction with an extended half-life supporting Q8W and Q4W subcutaneous dosing.

Summary of the filing

Viridian Therapeutics announced positive Phase 1 clinical trial results for VRDN-008, a half-life extended bispecific FcRn inhibitor, demonstrating deep and sustained IgG reduction with an extended half-life supporting Q8W and Q4W subcutaneous dosing. The company plans to initiate at least one pivotal trial in 2027, starting with myasthenia gravis in mid-2027.

For details, click here →How to read a 8-K →

Key details

RegistrantViridian Therapeutics, Inc.
President and chief executive officerStephen Mahoney

✦ Ask GOAX AI about this filing — what it means for VRDN, what changed since its last filings and what to watch next.

Try it free for 7 days

🔔 Want to stay updated on new SEC filings for VRDN?

Click here

Frequently asked questions

What did VRDN file with the SEC on Nov 9, 2026?

VRDN filed a 8-K (Fda approval). Viridian Therapeutics announced positive Phase 1 clinical trial results for VRDN-008, a half-life extended bispecific FcRn inhibitor, demonstrating deep and sustained IgG reduction with an extended half-life supporting Q8W and Q4W subcutaneous dosing. The company plans to initiate at least one pivotal trial in 2027, starting with myasthenia gravis in mid-2027.

What does a fda approval mean for VRDN stock?

For a small biotech one drug can be most of the company’s value. Approval opens sales; a rejection (complete response letter) can delay it by years.

How do I read a 8-K?

A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more. The "Item" number tells you the topic (e.g. 2.02 results, 5.02 executive change, 1.01 new agreement, 1.03 bankruptcy). Exhibits (99.1 press release) usually hold the details.

Why are SEC filings important?

Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A 8-K (current report): A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more.

Other VRDN SEC filings

Get alerts when VRDN files with the SEC, plus live charts, key levels and news for 13,000+ stocks.

Try SEPT free for 7 days
VRDN overviewVRDN analysisVRDN newsLatest SEC filings